A detailed history of Teza Capital Management LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Teza Capital Management LLC holds 25,159 shares of IONS stock, worth $953,777. This represents 0.15% of its overall portfolio holdings.

Number of Shares
25,159
Previous 29,936 15.96%
Holding current value
$953,777
Previous $1.3 Million 7.56%
% of portfolio
0.15%
Previous 0.17%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$36.45 - $47.7 $174,121 - $227,862
-4,777 Reduced 15.96%
25,159 $1.2 Million
Q1 2024

May 15, 2024

BUY
$42.03 - $53.55 $849,132 - $1.08 Million
20,203 Added 207.57%
29,936 $1.3 Million
Q4 2023

Feb 14, 2024

BUY
$43.39 - $51.63 $105,047 - $124,996
2,421 Added 33.11%
9,733 $492,000
Q3 2023

Nov 14, 2023

BUY
$38.5 - $47.13 $5,428 - $6,645
141 Added 1.97%
7,312 $331,000
Q2 2023

Feb 22, 2024

SELL
$34.73 - $43.33 $159,723 - $199,274
-4,599 Reduced 47.25%
5,134 $210,000
Q2 2023

Aug 14, 2023

BUY
$34.73 - $43.33 $249,048 - $310,719
7,171 New
7,171 $294,000
Q4 2022

Feb 14, 2023

BUY
$37.12 - $46.52 $88,197 - $110,531
2,376 Added 23.19%
12,624 $476,000
Q3 2022

Nov 14, 2022

SELL
$36.54 - $48.66 $72,239 - $96,200
-1,977 Reduced 16.17%
10,248 $453,000
Q2 2022

Aug 15, 2022

BUY
$31.71 - $43.0 $149,258 - $202,401
4,707 Added 62.61%
12,225 $453,000
Q1 2022

May 16, 2022

SELL
$29.88 - $37.04 $129,290 - $160,272
-4,327 Reduced 36.53%
7,518 $278,000
Q4 2021

Feb 14, 2022

BUY
$25.61 - $35.1 $303,350 - $415,759
11,845 New
11,845 $360,000
Q3 2020

Nov 12, 2020

SELL
$47.45 - $62.95 $272,790 - $361,899
-5,749 Closed
0 $0
Q2 2020

Aug 10, 2020

SELL
$46.85 - $61.05 $66,480 - $86,629
-1,419 Reduced 19.8%
5,749 $339,000
Q1 2020

May 11, 2020

BUY
$41.6 - $63.4 $298,188 - $454,451
7,168 New
7,168 $339,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.38B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Teza Capital Management LLC Portfolio

Follow Teza Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Teza Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Teza Capital Management LLC with notifications on news.